New HIV drug candidate GS-1219 tested in tiny early trial
NCT ID NCT07115368
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This was a small, early-phase study testing an experimental HIV drug called GS-1219 in just 4 people living with HIV-1. The goal was to check the drug's safety and how well it fights the virus. The study was terminated early, so results are very limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GS-1219 (an experimental antiretroviral drug)
What this could lead to
If successful, GS-1219 could become a new option for controlling HIV-1, adding to the arsenal of antiretroviral therapies.
What could go wrong
This was a very early (Phase 1), tiny (4 participants) study that was terminated, so we have very limited data. The drug may not prove effective or safe in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AXCES Research Group
El Paso, Texas, 79902, United States
-
AXCES Research Group
Salt Lake City, Utah, 84102, United States
-
BLISS Health Inc
Orlando, Florida, 32803, United States
-
Be Well Medical Center
Berkley, Michigan, 48072, United States
-
Central Texas Clinical Research
Austin, Texas, 78705, United States
-
Midland Florida Clinical Research Center
DeLand, Florida, 32720, United States
-
Midway Immunology and Research Center
Ft. Pierce, Florida, 34982, United States
-
Mills Clinical Research
Los Angeles, California, 90069, United States
-
North Texas Infectious Diseases Consultants
Dallas, Texas, 75246, United States
-
Orlando Immunology Center
Orlando, Florida, 32803, United States
-
Prism Health North Texas
Dallas, Texas, 75208, United States
-
Quest Clinical Research
San Francisco, California, 94115, United States
-
Ruane Clinical Research Group
Los Angeles, California, 90036, United States
-
Triple O Research Institute
West Palm Beach, Florida, 33407, United States
-
Washington Health Institute
Washington D.C., District of Columbia, 20017, United States